Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
-
- STATUS
- Recruiting
-
- End date
- Feb 28, 2022
-
- participants needed
- 331
-
- sponsor
- DBV Technologies
Lara Ford, MD
Primary Contact
The Children's Hospital at Westmead (7.7 mi away) Contact
+50 other locationSummary
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
Details
| Treatment | Placebo, Viaskin Peanut 250 mcg, Viaskin Peanut 100 mcg |
|---|---|
| Clinical Study Identifier | NCT03211247 |
| Sponsor | DBV Technologies |
| Last Modified on | 1 November 2020 |
Adding a note
Select a piece of text and start making personal notes.
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer